How should antithrombin III (ATIII) deficiency be diagnosed and managed?

Antithrombin III Deficiency: Diagnosis and Management

For patients with suspected or confirmed antithrombin III (ATIII) deficiency, initiate anticoagulation with low-molecular-weight heparin (LMWH) for acute venous thromboembolism and consider indefinite anticoagulation for those with idiopathic thrombosis or recurrent events, while using ATIII concentrate replacement in high-risk situations such as surgery, pregnancy, or when heparin resistance occurs.

Diagnosis

Laboratory Testing Approach

Use an ATIII activity assay as the initial screening test 1. When activity levels are low:

• Perform an antigen test to calculate the activity-to-antigen ratio
• This ratio helps distinguish Type I (quantitative, both low) from Type II (qualitative, discordant results) deficiency 1

Critical Testing Considerations

Exclude acquired causes before diagnosing hereditary deficiency 1:

• Liver dysfunction (decreased synthesis)
• Proteinuria/nephrotic syndrome (urinary loss)
• Active heparin therapy (consumption)
• Disseminated intravascular coagulation (consumption)
• Acute thrombosis (consumption)
• Recent surgery (consumption)

Medication Interference

Be aware that certain anticoagulants cause falsely normal or elevated results 1:

• Factor IIa-based assays: Argatroban, bivalirudin, dabigatran interfere
• Factor Xa-based assays: Rivaroxaban, apixaban, edoxaban interfere (betrixaban does not)

Pediatric Considerations

Use pediatric reference ranges until 6 months of age, as normal newborns have ATIII levels 20-80% of adult values 2.

Genetic Testing

Molecular testing, when available, helps determine thrombosis risk as this varies among mutations 1. The Budapest 3 variant (p.Leu131Phe) is the most common Type II/heparin-binding site deficiency in Europe, particularly in Roma populations 3.

Risk Stratification

Thrombosis Risk

ATIII deficiency carries the highest VTE risk among hereditary thrombophilias 4, 5. Risk is particularly elevated during:

• Pregnancy and postpartum period 5, 6
• Major surgery 5
• Prolonged immobilization 5
• Hormonal therapy (oral contraceptives, estrogen replacement) 7

Recurrence Risk Classification

Based on the index thrombotic event 8, 9:

• **Low risk (<3%/year)**: Major transient/reversible factors (surgery >30 min, hospitalization ≥3 days)
• High risk (>8%/year): Idiopathic thrombosis, recurrent VTE, or hereditary thrombophilia including ATIII deficiency

Acute Management

Initial Anticoagulation

For acute VTE, initiate therapeutic anticoagulation immediately 8:

• LMWH is preferred over unfractionated heparin 6
• Enoxaparin 1 mg/kg subcutaneously every 12 hours, OR
• Dalteparin 200 units/kg subcutaneously daily

Heparin Resistance

ATIII deficiency causes heparin resistance, defined as inability to achieve ACT >300 seconds after >600 U/kg heparin 2. When this occurs:

Administer ATIII concentrate 500 U IV, repeat once as needed to reach desired ACT 10. Target ATIII activity:

• ≥120% preoperatively 11
• ≥80% postoperatively 11
• Maintain ACT >400 seconds during cardiopulmonary bypass 11

Alternative if ATIII concentrate unavailable: Fresh frozen plasma (FFP), though less optimal due to volume load and lack of viral inactivation 2.

Long-Term Anticoagulation

Duration of Therapy

Indefinite anticoagulation is indicated for 8:

• One episode of idiopathic proximal vein thrombosis with ATIII deficiency
• Recurrent venous thrombosis
• ATIII deficiency with history of thrombosis

The rationale: At 12% annual recurrence rate, death risk from recurrent thromboembolism (5-7% case fatality) exceeds bleeding risk from anticoagulation (0.6% annual case fatality) 8.

Anticoagulant Selection

Warfarin (INR 2.0-3.0) remains the standard 8:

• Moderate-intensity (INR 2.0-3.0) is as effective as high-intensity (INR 3.0-4.5) with less bleeding 8
• Long-term experience makes it preferred until pharmacokinetic studies with newer agents are completed 12

Direct oral anticoagulants (DOACs) are effective alternatives:

• Apixaban successfully used in case reports 7
• DOACs work independently of ATIII levels 7
• However, limited data in ATIII deficiency populations 12

Special Clinical Scenarios

Pregnancy Management

All pregnant women with ATIII deficiency and prior VTE require full-dose LMWH throughout pregnancy and postpartum 6:

• Continue therapeutic dosing (e.g., enoxaparin 1 mg/kg every 12 hours)
• Postpartum period carries highest risk

For pregnant women without prior VTE, assess individual risk factors 6:

• Type and severity of ATIII deficiency
• Family history of VTE
• Additional pregnancy-specific risk factors

ATIII concentrate indications in pregnancy 6:

• Childbirth when anticoagulation must be withheld
• Acute VTE despite therapeutic anticoagulation
• Perioperative period (cesarean section)

Target ATIII levels: Maintain >80% during high-risk periods 13.

Surgical Management

Preoperative preparation 11:

1. Achieve ATIII activity ≥120% before surgery using ATIII concentrate
2. Maintain ACT >400 seconds during cardiopulmonary bypass
3. Keep postoperative ATIII activity ≥80%

Postoperative anticoagulation:

• Resume therapeutic anticoagulation when hemostasis achieved
• Long-term anticoagulation necessary in hereditary ATIII deficiency with thrombosis history 11

Neuraxial Anesthesia

Regional anesthesia is not absolutely contraindicated but requires meticulous planning 14:

• Ensure ATIII levels are safe (>80%) at time of puncture
• Use ATIII concentrate to maintain adequate levels perioperatively
• Requires multidisciplinary coordination between anesthesia, hematology, and obstetrics

Common Pitfalls

1. Testing during acute thrombosis or anticoagulation: ATIII levels are consumed during active clotting and affected by heparin—delay testing until 2-4 weeks after event and off anticoagulation when possible 1

2. Assuming all ATIII deficiency is high-risk: Type II heparin-binding site defects (like Budapest 3) are generally milder than Type I quantitative defects 3

3. Inadequate ATIII replacement during surgery: Failure to achieve target levels (≥120% pre-op, ≥80% post-op) increases thrombotic complications 11

4. Stopping anticoagulation after first event: Unlike other thrombophilias, ATIII deficiency warrants indefinite anticoagulation after even a single idiopathic VTE 8

5. Overlooking estrogen exposure: Combined oral contraceptives significantly increase arterial and venous thrombosis risk—absolute contraindication in ATIII deficiency 7

Family Screening

Screen first-degree relatives of patients with confirmed hereditary ATIII deficiency 5:

• Genetic testing identifies at-risk family members
• Counsel regarding avoidance of estrogen therapy, thrombosis risk during pregnancy/surgery
• Consider prophylactic anticoagulation for high-risk situations even without prior thrombosis